Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) have been given an average rating of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. Eight ...

Equities research analysts at Wedbush reduced their Q1 2025 earnings per share estimates for shares of Voyager Therapeutics ...

Voyager Therapeutics announced positive results from the single ascending dose (SAD) trial of its investigational anti-tau antibody, VY7523, which demonstrates safety, tolerability, and dose ...

Pete Stavropoulos; Analyst; Cantor Fitzgerald & Co. Good afternoon and welcome to Voyager Therapeutics fourth-quarter and year-end 2024 financial results conference call. (Operator Instructions ...

Voyager Therapeutics (VYGR) announced positive topline data from the Company’s single ascending dose, SAD, trial of VY7523, an investigational anti-tau antibody developed to selectively inhibit ...

Voyager Therapeutics, Inc. LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines ...

The latest price target for Voyager Therapeutics (NASDAQ:VYGR) was reported by Canaccord Genuity on March 13, 2025. The analyst firm set a price target for $12.00 expecting VYGR to rise to within ...

(RTTNews) - Voyager Therapeutics, Inc. (VYGR) Monday announced positive topline data from its single ascending dose (SAD) study of VY7523 developed for the treatment of Alzheimers disease (AD).